Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance

Cancer Research

Volumn 64, Issue 19, 2004, Pages 7130-7138

  Muñoz Martínez, Francisco ^a   Lu, Peihua ^b   Cortés Selva, Fernando ^a   Pérez Victoria, José María ^a   Jiménez, Ignacio A ^c   Ravelo, Ángel G ^c   Sharom, Frances J ^b   Gamarro, Francisco ^a   Castanys, Santiago ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b UNIVERSITY OF GUELPH   (Canada)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

28 DIHYDRO BETA AGAROFURAN SESQUITERPENE; ADENOSINE TRIPHOSPHATASE; AZIDOPINE H 3; BREAST CANCER RESISTANCE PROTEIN; COLCHICINE DERIVATIVE; COLCHICINE H 3; DAUNORUBICIN; DIHYDROPYRIDINE DERIVATIVE; GLYCOPROTEIN P; HOE 33342; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; SESQUITERPENE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELASTRACEAE; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; FLOW CYTOMETRY; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEOLIPOSOME;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; AZIDES; BENZIMIDAZOLES; BINDING, COMPETITIVE; CELASTRACEAE; CELL MEMBRANE; DAUNORUBICIN; DIHYDROPYRIDINES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUORESCEINS; HUMANS; KINETICS; LIPOSOMES; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NIH 3T3 CELLS; P-GLYCOPROTEIN; PHOTOAFFINITY LABELS; PROTEIN BINDING; SESQUITERPENES; SUBSTRATE SPECIFICITY; VINBLASTINE;

EID: 4944232223     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1005     Document Type: Article

References (44)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
2. Ueda K, Cardareili C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004-8.
3. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Wash DC) 1992;258:1650-4.
4. Chen ZS, Kawabe T, Ono M, et al. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 1999;56:1219-28.
5. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70.
6. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086-99.
7. van der Kolk DM, de Vries EG, van Putten WJ, et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 2000;6:3205-14.
8. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003;10:159-65.
9. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst (Bethesda) 1995;87:1593-602.
10. Sikic BI. Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 1997;34:40-7.
11. Chan HS, DeBoer G, Thiessen JJ, et al. Combining cydosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 1996;2:1499-508.
12. Belpomme D, Gauthier S, Pujade-Lauraine E, et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 2000;11:1471-6.
13. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin N Am 1995;9:363-82.
14. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265-83.
15. Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem 2003;46:4805-17.
16. Spivey AC, Weston M, Woodhead S. Celastraceae sesquiterpenoids: biological activity and synthesis. Chem Soc Rev 2002;31:43-59.
17. Perez-Victoria JM, Tincusi BM, Jimenez IA, et al. New natural sesquiterpenes as modulators of daunomycin resistance in a multidrug-resistant Leishmania tropica line. J Med Chem 1999;42:4388-93.
18. Kennedy ML, Cortes-Selva F, Perez-Victoria JM, et al. Chemosensitization of a multidrug-resistant Leishmania tropica line by new sesquiterpenes from Maytenus magellanica and Maytenus chubutensis. J Med Chem 2001;44:4668-76.
19. Gonzalez AG, Tincusi BM, Bazzocchi IL, et al. Anti-tumor promoting effects of sesquiterpenes from Maytenus cuzcoina (Celastraceae). Bioorg Med Chem 2000;8:1773-8.
20. Gonzalez AG, Jimenez IA, Ravelo AG, Bazzocchi IL. β-Agarofuran sesquiterpenes from Maytenus canariensis. Phytochemistry 1990;29:2577-9.
21. Cortes-Selva F, Campillo M, Reyes CP, et al. SAR studies of dihydro-beta-agarofuran sesquiterpenes as inhibitors of the multidrug-resistance phenotype in a Leishmania tropica line overexpressing a P-glycoprotein-like transporter. J Med Chem 2004;47:576-87.
22. Cardarelli CO, Aksentijevich I, Pastan I, Gottesman MM. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res 1995;55:1086-91.
23. Kartner N, Evemden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature (Lond) 1985;316:820-3.
24. Evers R, Kool M, van Deemter L, et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Investig 1998;101:1310-9.
25. Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999;96:6914-9.
26. Erlichman C, Boerner SA, Hallgren CG, et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 2001;61:739-48.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
28. Sharom FJ, DiDiodato G, Yu X, Ashbourne KJ. Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores. J Biol Chem 1995;270:10334-41.
29. Eisenthal R, Cornish-Bowden A. The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem J 1974;139:715-20.
30. Doige CA, Sharom FJ. Strategies for the purification of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Protein Expr Purif 1991;2:256-65.
31. Liu R, Sharom FJ. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry 1996;35:11865-73.
32. Lu P, Liu R, Sharom FJ. Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state. Eur J Biochem 2001;268:1687-97.
33. Safa AR, Glover CJ, Sewell JL, et al. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 1987;262:7884-8.
34. Sharom FJ, Yu X, DiDiodato G, Chu JW. Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. Biochem J 1996;320(Pt 2):421-8.
35. Liu R, Siemiarczuk A, Sharom FJ. Intrinsic fluorescence of the P-glycoprotetn multidrug transporter: sensitivity of tryptophan residues to binding of drugs and nucleotides. Biochemistry 2000;39:14927-38.
36. Sharom FJ, Yu X, Lu P, et al. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem Pharmacol 1999;58:571-86.
37. Liu R, Sharom FJ. Fluorescence studies on the nucleotide binding domains of the P-glycoprotein multidrug transporter. Biochemistry 1997;36:2836-43.
38. Qu Q, Sharom FJ. Proximity of bound Hoechst 33342 to the ATPase catalytic sites places the drug binding site of P-glycoprotein within the cytoplasmic membrane leaflet. Biochemistry 2002;41:4744-52.
39. Litman T, Zeuthen T, Skovsgaard T, Stein WD. Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta 1997;1361:159-68.
40. Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56:4171-9.
41. Shtil AA. P-glycoprotein as a therapeutic target: good news. Leukemia (Baltimore) 2002;16:2169-70.
42. Lehne G, Sorensen DR, Tjonnfjord GE, et al. The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice. Leukemia (Baltimore) 2002;16:2388-94.
43. Loo TW, Clarke DM. Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem 2002;277:44332-8.
44. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV. Evidence for two nonidentical drug-interaction sites in the human P-glycoproiein. Proc Natl Acad Sci USA 1997;94:10594-9.